THE BLOOD FACTOR
-
Important survey about hemophilia B gene therapy – THE CLOCK IS TICKING!
The 1st gene therapy for hemophilia B (factor IX deficiency) is currently undergoing an evaluation by Canadian health authorities. This review will determine whether or...
-
Justice Krever is no longer with us … but his legacy is very much alive
The Commission of Inquiry on the Blood System in Canada was a public investigation of the Canadian blood system, which had been contaminated with HIV...
-
Update on coagulation products – current and in the pipeline
To access charts informing you of products in the PIPELINE, please CLICK HERE. To access charts informing you of CURRENT coagulation products, please CLICK HERE....
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Héma-Québec tender selects an extended half-life FVIII
Héma-Québec announced on November 30, following its Request for Proposals for recombinant factor VIII concentrates, that it had selected Esperoct. Esperoct is approved by Health...